Cargando…
Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity
[Image: see text] Multiple myeloma (MM), a plasma cell cancer in bone marrow, remains an incurable disease. Melphalan, an alkylating agent, is a conventional anticancer drug that is still widely used for MM treatment in clinics. However, melphalan-induced organ toxicity and side effects are common....
Autores principales: | Lin, Zhimei, Chu, Bingyang, Qu, Ying, Wei, Xue, Huang, Jingcao, Wang, Fangfang, Feng, Yu, Wang, Xin, Luo, Hongmei, Zhai, Xinyu, Xu, Juan, Liu, Xiang, Zhang, Li, Chen, Fengjiao, Wu, Yu, Zheng, Yuhuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835516/ https://www.ncbi.nlm.nih.gov/pubmed/36643473 http://dx.doi.org/10.1021/acsomega.2c07555 |
Ejemplares similares
-
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
por: Yang, Yan, et al.
Publicado: (2022) -
Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis
por: Chen, Xue-han, et al.
Publicado: (2019) -
Bisphosphonates as antimyeloma drugs
por: Modi, N D, et al.
Publicado: (2012) -
Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021) -
ALCAM regulates multiple myeloma chemoresistant side population
por: Wang, Fangfang, et al.
Publicado: (2022)